Journal of Viral Hepatitis

Article	Citations
Issue Information	44
Issue Information	42
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study	33
Issue Information	33
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study	29
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab	27
	25
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	24
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	22
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working‐age adults in Madrid (Spain)	22
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease	21
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues	20
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C	20
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination	20
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents	20
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection	19
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	19
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	19
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	18
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	18
Issue Information	17
Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections	16
Reversibility of acute‐on‐chronic liver failure syndrome in hepatitis B virus‐infected patients with and without prior decompensation	16
	16
Integration and the risk of liver cancer—Is there a real risk?	15

Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment	15
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies	15
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	15
Issue Information	15
Infectivity of Hepatitis B Virus Surface Antigen‐Positive Plasma With Undetectable HBV‐DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	14
TRPM2 regulates autophagy to participate in hepatitis B virus replication	14
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma	14
A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma	14
Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment	14
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study	13
Issue Information	13
Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study	13
Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department	13
Issue Information	13
Adenovirus vector encoding TPPII ignites HBV‐specific CTL response by activating autophagy in CD8+ T cell	13
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone	13
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study	13
The role of treatment of hepatitis C with direct‐acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta‐analysis	13
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study	13
Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver‐related complications in patients with chronic hepatitis C receiving direct‐acting antiviral agents	13
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic	12
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale	12
Viral hepatitis in pregnancy	12
Serum HBV RNA is associated with liver fibrosis regression in HBeAg‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues	11
Epidemiology and Outcomes of Hepatitis E Virus‐Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998–2020	11
Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis	11
Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO‐PLUS study	11
Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients	11
	10
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis	10
Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection:	10
Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States	10
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review	10
	10
Network‐basedstrategies to combatHCV: Examining social and spatial drivers of transmission amongPWIDin New Delhi	10
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis	9
An updated assessment of hepatitis delta prevalence among adults in Canada: A meta‐analysis	9
Epidemiological Burden of Hepatitis Delta Virus in the United States	9
Efficacy of an eConsult service to cure hepatitis C in primary care	9
Issue Information	9
A declaration from people living with hepatitis B: A call for a whole person approach	9
Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals	9
Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature	9
	9
Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone	9
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study	9
Cover image	9
Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis	9
Hepatitis B e antigen and e antibody in a multi‐ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years	8
Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients	8

Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study	8
The altered HLA‐DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells	8
CHB patients with rtA181T‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes	8
Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection	8
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States	8
VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department	8
Hepatitis D virus infection: Progress on the path toward disease control and cure	8
Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatme	8
Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B	7
A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP‐HEPC t	7
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™	7
Issue Information	7
Screening rates for hepatitis B and C among low‐income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study	7
A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022	7
Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive	7
Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population	7
	7
Risk factors for hepatitis C virus infection at a large urban emergency department	7
Impact of COVID‐19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs	7
Prognostic value of genotyping in hepatocellular carcinoma: A systematic review	7
Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather)	7
The immune landscape in hepatitis delta virus infection—Still an open field	7
	7
A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons	7
Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa	7
MELD score < 18 rule out 28‐day ACLF development among inpatients with hepatitis B‐related previous compensated liver disease	6
Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis	6
	6
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers	6
Hepatitis Delta Coinfection Rates and All‐Cause Mortality Among Hepatitis B‐Infected Veterans in the USA	6
Persistent chronic immune activation in HIV/HBV‐coinfected patients after antiretroviral therapy	6
Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B	6
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH)	6
Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure	6
	6
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis	6
Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women	6
Barriers and enablers to people‐centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study	6
Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal	6
Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy	6
Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’	6
CORRIGENDUM	6
Issue Information	6
Long‐term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	6
Mortality and morbidity related to hepatitis C virus infection in hospitalized adults—A propensity score matched analysis	6
Reply to Wang et al	6
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals	6
Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?	5
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection	5
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	5
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study	5
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy	5
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway	5
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B	5
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up	5
	5
Maternal chronic hepatitis B virus infection and the risk of preterm birth: A retrospective cohort analysis in Chinese women	5
MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment	5
A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype	5
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C	5
	5
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city	5
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data	5
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy	5
	5
Post‐vaccination serologic testing of infants born to hepatitis B surface antigen‐positive mothers is more cost‐effective in Zhejiang Province, China: A Markov chain analysis	5
Sequence characterization of extracellular HBV RNA in patient plasma	5
Cover Image	5
Prevalence of hepatitis C among pregnant women in an Appalachian population	5
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China	5
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus	5
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United	5
Closing the hepatitis C treatment gap: United States strategies to improve retention in care	5
Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir	5
Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity	5
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	4
Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial	4
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	4
Comparison of acknowledged hepatocellular carcinoma risk scores in high‐risk hepatitis C patients with sustained virological response	4
Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero‐surveys in 2007 and 2019	4

Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B‐related cirrhosis: Multicentre real‐world observational study	4
	4
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic	4
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection	4
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	4
Issue Information	4
Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days	4
	4
Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment	4
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	4
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B‐coinfected adults in care in the United States	4
Hepatitis C active viremia over time in an ED‐based testing programme: Impact, disparities and surveillance tool	4
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis	4
Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education	4
Hepatitis B Care and Treatment in Zanzibar, Tanzania: A Demonstration Project Following 2015 WHO Treatment Guidelines, 2017–2021	4
	4
Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus	4
Regarding the predictive role of CXCL16 in liver inflammation in chronic hepatitis B patients	4
	4
Reply to: ‘Abnormal liver function tests and coronavirus disease 2019: A close relationship’	4
Hepatitis after gene therapy, what are the possible causes?	4
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply	4
Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection	4
Psychiatrists can treat hepatitis C	4
	4
Determining the frequency and characteristics of Hepatitis C reinfections in North East England	4
Community Pop‐Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner‐City PWID Populations	4
Issue Information	4
Epidemiology, linkage to care and natural history of women of childbearing age with chronic hepatitis B: A population‐based study	4
The 5‐year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment	4
Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy	4
Issue Information	4
Testing to sustain hepatitis C elimination targets in people who inject drugs: A network‐based model	4
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	4
Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States	4